Skip to main content

Table 7 Risk factor analysis for major bleeding occurrence within 1 year after lung cancer diagnosis

From: Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study

  UnivariateMultivariate**
  sHR (95% CI)p-valuesHR (95% CI)p-value
Age<  65
≥ 651.38 (1.11–1.71)0.0041.40 (1.11–1.76)0.005
GenderMale
Female0.68 (0.53–0.87)0.0020.73 (0.57–0.94)0.016
Metastasis 1.58 (1.26–1.98)< 0.00011.38 (1.08–1.78)0.011
PE 2.88 (1.83–4.52)< 0.00012.90 (1.85–4.54)< 0.0001
DVT 1.53 (0.96–2.43)0.074  
Anticoagulant therapy 1.91 (1.41–2.59)< 0.00011.77 (1.30–2.43)0.0003
Antiplatelet therapy 1.36 (1.09–1.71)0.0071.27 (1.01–1.60)0.044
NSAID therapy 0.71 (0.49–1.03)0.075  
Lung cancer surgery 1.79 (1.33–2.42)0.00012.54 (1.88–3.45)< 0.0001
Other surgery 1.68 (1.26–2.23)0.00041.50 (1.11–2.02)0.009
Chemotherapy 1.66 (1.30–2.13)< 0.00011.54 (1.19–2.00)0.001
Bevacizumab 1.04 (0.49–2.21)0.919  
Oral targeted therapy 0.97 (0.47–1.97)0.925  
Radiotherapy 1.80 (1.34–2.41)0.00011.71 (1.25–2.34)0.001
  1. **Multivariate analysis adjusted for age and gender